跳转至内容
Merck
CN

PHR1382

Supelco

头孢曲松钠

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

头孢曲松 二钠盐 半(七水合物)

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C18H16N8Na2O7S3 · 3.5H2O
化学文摘社编号:
104376-79-6
分子量:
661.60
EC 号:
277-930-0
MDL编号:
MFCD01750405
UNSPSC代码:
41116107
PubChem化学物质编号:
329823359
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material
pharmaceutical secondary standard

质量水平

300

Agency

USP 1098184
traceable to Ph. Eur. C0691000

API类

ceftriaxone

CofA

current certificate can be downloaded

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChI key

PMRZKYOXTPBIQF-MAODNAKNSA-J

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

应用

Ceftriaxone Sodium may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and serum samples by various chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

其他说明

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
To see an example of a Certificate of Analysis for this material enter LRAC3447 in the slot below. This is an example certificate only and may not be the lot that you receive.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Danger

危险分类

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Validation of an HPLC-UV method for the determination of ceftriaxone sodium residues on stainless steel surface of pharmaceutical manufacturing equipments
Akl MA, et al.
Journal of Pharmaceutical and Biomedical Analysis, 55(2), 247-252 (2011)
Simultaneous determination of ceftriaxone sodium and statin drugs in pharmaceutical formulations and human serum by RP-HPLC.
Sultana N, et al.
Journal of the Chilean Chemical Society, 55(2), 193-198 (2010)
Simultaneous Determination of Ceftriaxone Sodium and Non Steroidal Anti?Inflammatory Drugs in Pharmaceutical Formulations and Human Serum by RP?HPLC.
Sultana N, et al.
J. Chin. Chem. Soc., 57(6), 1278-1285 (2010)
Ning Li et al.
Pediatrics, 133(4), e917-e922 (2014-03-26)
Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children. We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history
Yi Yao et al.
Pharmacoepidemiology and drug safety, 21(11), 1197-1201 (2012-07-05)
The incidence of adverse reactions to ceftriaxone, which is widely used in China, has gradually increased, with an associated increase in patient fatality. An analysis of the reported data from articles published in China highlights the importance and extent of
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持